OHSU

Drug Effectiveness Review Project (DERP)

Drug Effectiveness Review Project (DERP)

DERP is a trailblazing collaborative of state Medicaid and public pharmacy programs dedicated to producing comparative, evidence-based research products that assist policymakers and other decision-makers grappling with difficult drug coverage decisions.

Nationally recognized for its clinical objectivity and high-quality research, DERP focuses on specialty and other high-impact drugs— particularly those that have potential to change clinical practice. DERP reports evaluate efficacy, effectiveness, and safety of drugs to ultimately help improve patient safety and quality of care while helping government programs contain exploding costs for new therapies.

Recent DERP Reports

  • Anticoagulants, Newer Oral
  • Antipsychotics, Second Generation
  • Asthma & Chronic Obstructive Pulmonary
  • Disease, Drugs to Treat
  • Diabetes Medications & Combinations, Newer
  • Injectable Oncology Drugs: Approved Indications & Codes
  • Lipid Lowering Drugs
  • Stimulants for ADHD: An Analysis of State & Policy
  • Guidelines
  • Multiple Sclerosis, Disease-modifying Drugs
  • Oral Oncology Agents: Indications, Codes, NCCN
  • Guideline Recommendations & Payer Policies
  • Psychotropics in Children: Academic Detailing
  • Targeted Immune Modulators

Proprietary DERP Clearinghouse

Click here to access the DERP Clearinghouse

Learn More About DERP

DERP reports and products are proprietary and only available to participating organizations. To learn about joining DERP, contact Susan Aromaa (aromaa@ohsu.edu) or download our brochure.

 

Join the DERP Distribution List

If you would like to join our e-mail list to learn about opportunities to comment on DERP reports and/or submit dossier information, please e-mail Susan Aromaa (aromaa@ohsu.edu).

 

DERP Reports Currently in Progress

For a list of reports currently in progress and for public comment and dossier submission dates, download the most recent DERP Report timeline.